Defining the susceptibility of colorectal cancers to BH3-mimetic compounds
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index; none of the 5 sources its claims cite is checked for support yet.
Abstract
Novel targets are required to improve the outcomes for patients with colorectal cancers. In this regard, the selective inhibitor of the pro-survival protein BCL2, venetoclax, has proven highly effective in several hematological malignancies. In addition to BCL2, potent and highly selective small molecule inhibitors of its relatives, BCLxL and MCL1, are now available, prompting us to investigate the susceptibility of colorectal cancers to the inhibition of one or more of these pro-survival proteins. While targeting BCLxL, but not BCL2 or MCL1, on its own had some impact, most (15/17) of the immortalized colorectal cancer cell lines studied were efficiently killed by the combined targeting of BCLxL and MCL1. Importantly, these in vitro findings were confirmed in a xenograft model and, interestingly, in all (5/5) patient derived tumor organoids evaluated. Our results lend strong support to the notion that BCLxL and MCL1 are highly promising targets for further evaluation in efforts to improve the treatment of colorectal cancers.
Overview
CoChat Summary
TL;DR
In colorectal cancer models, BCLxL is the primary pro-survival dependency, but dual targeting of BCLxL and MCL1 is required to efficiently kill most cell lines and all patient-derived organoids tested. The findings support further evaluation of BCLxL/MCL1 co-inhibition, while noting potential on-target toxicities.
Key findings
In 17 immortalized human CRC cell lines, BCLxL inhibition alone killed 3/17; MCL1 or BCL2 inhibition alone was ineffective. Combined BCLxL + MCL1 killed 15/17, and adding BCL2 did not improve killing.
- BH3-mimetic killing was apoptosis-specific: it was fully abrogated in BAX−/−BAK−/− HCT116 cells. RKO showed delayed responses, while LoVo was highly refractory and harbors inactivating BAX mutations.
- In SW480 xenografts in NSG mice, targeting BCLxL or MCL1 alone modestly suppressed tumor growth, while co-targeting both had a deeper impact.
- In 5 patient-derived tumor organoids, 3/5 were variably sensitive to BCLxL inhibition alone; all 5 were killed by combined BCLxL/MCL1/BCL2 inhibition. Dependencies: CRC#1 predominantly BCLxL; MCL1 also important in CRC#2–4; BCL2 contributed additionally in CRC#5.
Methods
In vitro: 17 human CRC cell lines treated with selective BH3 mimetics against BCL2 (venetoclax), BCLxL (A1331852), or MCL1 (S64845), alone or in equimolar combinations; viability by CellTiter-Glo after 6 h (some 6–96 h), with IC50 heatmaps and mean IC50s ± SD from three independent experiments where indicated.
- In vivo: SW480 cells engineered to inducibly express MCL1-selective peptide BIM2A or inert BIM4E control were inoculated subcutaneously into immunodeficient NSG mice; A1331852 25 mg/kg on weekdays for 2 weeks plus doxycycline food; tumor volumes monitored every 2–3 days (three mice/group).
- Patient-derived organoids: n = 5 treated with 0–1.25 μM BH3 mimetics alone or in equimolar combinations; viability at 24 h, mean IC50s of two independent experiments; rapid apoptosis assessed by propidium iodide staining and imaging.
Limitations
Stated: co-targeting BCLxL and/or MCL1 may be challenging because of on-target toxicities; the authors suggest antibody–drug conjugates to restrict action to tumor cells and call for further laboratory studies.
- Evident from the text: small sample sizes (17 cell lines, 5 organoids, 3 mice per xenograft group), short-term in vitro viability assays, and no clinical validation; organoid heterogeneity and BAX-mutant LoVo resistance may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
0 Valid · 0 Not valid · 3 Not checked · 16 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Remarkably, 3/5 tumor organoids (CRC#1–3) were variably sensitive to BCLxL inhibition alone (Fig. 1e).”
§ Defining the susceptibility of colorectal cancers to BH3-mimetic compounds > Abstract
plainstates a causen = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RKO cells showed delayed responses (Fig. 1c)”
§ Defining the susceptibility of colorectal cancers to BH3-mimetic compounds > Abstract
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rapid killing of these organoids by these BH3 mimetics was confirmed by the killing kinetics with propidium iodide staining analyzed by microscopic imaging (Fig. 1f, Supplementary Fig. 2b, and Supplementary Video 1).”
§ Defining the susceptibility of colorectal cancers to BH3-mimetic compounds > Abstract
plainstates a causen = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Strikingly, 15/17 lines were susceptible when BCLxL and MCL1 were both targeted”
- Also stated in: § Abstract · plain
“most (15/17) of the immortalized colorectal cancer cell lines studied were efficiently killed by the combined targeting of BCLxL and MCL1”
§ Defining the susceptibility of colorectal cancers to BH3-mimetic compounds > Abstract
boostedstates a causen = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the LoVo cells were highly refractory even with prolonged treatment”
§ Defining the susceptibility of colorectal cancers to BH3-mimetic compounds > Abstract
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
7 more claims
Create a free account to see all 19 claims and to verify the 5 references still open.
- It may state two separate claims as one. 4
- Probably not a substantial claim. 3
Citations
Cites
Minerva Access is the Institutional Repository of The University of Melbourne Author/s:
(n.d.) · Cited by 13,961
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C., & Perucho, M. (1997) · Science · doi:10.1126/science.275.5302.967 · Cited by 1,326
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
Self-citationHuman Organoids: Tools for Understanding Biology and Treating Diseases
Schutgens, F., & Clevers, H. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032611 · Cited by 510
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Merino, D., Kelly, G. L., Lessene, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 287
Lee, E. F., Czabotar, P. E., van Delft, M. F., Michalak, E. M., Boyle, M. J., Willis, S. N., Puthalakath, H., Bouillet, P., Colman, P. M., Huang, D. C. S., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708096 · Cited by 172
Self-citationSoderquist, R. S., Crawford, L. A., Liu, E., Lu, M., Agarwal, A., Anderson, G. R., Lin, K., Winter, P. S., Çakır, M., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-05815-z · Cited by 141
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Cited by
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
Synthesis of 1,3,4-Thiadiazole Derivatives and Their Anticancer Evaluation
Stecoza, C. E., Nițulescu, G. M., Draghici, C. C., Căproiu, M. T., Hanganu, A., Olaru, O. T., Mihai, D. P., Bostan, M., & Mihaila, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417476 · Cited by 41
Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers
Fairlie, W. D., & Lee, E. F. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210750 · Cited by 28
Zhang, L., Ramesh, P., Steinmetz, M., & Medema, J. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083811 · Cited by 16
Metadata
- Authors
- Luo, M.-J., Palmieri, M., Riffkin, C. D., Sakthianandeswaren, A., Djajawi, T. M., Hirokawa, Y., Shuttleworth, V., Segal, D. H., White, C. A., Nhu, D., Lessene, G., Lee, M., Gibbs, P., Huang, D. C. S., Sieber, O. M., & Gong, J.-N.
- Affiliations
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Huang, David C. S.
- Sieber, Oliver M.
- ORCID
- Venue
- Cell Death & Disease
- Published
- 2020-09-10
- Volume
- 11
- Issue
- 9
- Pages
- 735-735
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC7483443
- OpenAlex
- W3084257764
- Semantic Scholar
- 0f181fad8611170682c8192c2ef559c12c507e7a
- Cited by
- 19
- References
- 11
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 1 · 2022: 4 · 2021: 4
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- China Scholarship Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- colorectal cancer, BH3 mimetics, Bcl-xL, Mcl-1, Bcl-2, venetoclax, pro-survival proteins, colorectal cancer cell lines, xenograft models, patient-derived tumor organoids, apoptosis
- MeSH terms
- Animals, Disease Susceptibility, Humans, Peptide Fragments, Proto-Oncogene Proteins, Colorectal Neoplasms, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. https://app.cochat.ai/papers/10.1038/s41419-020-02815-0
- The paper
- Luo, M.-J., Palmieri, M., Riffkin, C. D., Sakthianandeswaren, A., Djajawi, T. M., Hirokawa, Y., Shuttleworth, V., Segal, D. H., White, C. A., Nhu, D., Lessene, G., Lee, M., Gibbs, P., Huang, D. C. S., Sieber, O. M., & Gong, J.-N. (2020). Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. Cell Death & Disease. https://doi.org/10.1038/s41419-020-02815-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.